Ifng-deficient BALB/cJ mice play key role in lymphoma vaccine
JAX® NOTES Issue 511, Fall 2008
With the help of JAX® Mice strain C.129S7(B6)-Ifngtm1Ts/J (002286), an interferon gamma (Ifng)-deficient mouse with a BALBc/J (000651) background, scientists recently moved one step closer to developing a vaccine against anaplastic large cell lymphoma (ALCL). The research team, headed by Dr. Giorgion Inghirami, University of Torino, Italy, showed that a combination of chemotherapy and DNA vaccination with plasmids encoding portions of the cytoplasmic domain of anaplastic lymphoma kinase (ALK) offers mice potent and long-lasting protection from local and systemic lymphoma (Chiarle et al. 2008). Because the ALK antigen is required for tumor growth, the vaccine may be an ideal vaccine against ALCL and other ALK+ human tumors. What role did the Ifng-deficient BALB/cJ mouse play in this research? Dr. Inghirami’s team used it to demonstrate that the vaccine doesn’t work without IFNG.
Reference
Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, Inghirami G. 2008. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14:676-80.
